Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

K. Metcalfe, S. Gershman, Henry T. Lynch, P. Ghadirian, N. Tung, C. Kim-Sing, O. I. Olopade, S. Domchek, J. McLennan, A. Eisen, W. D. Foulkes, B. Rosen, P. Sun, S. A. Narod

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Purpose:The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk.Patients and methods:Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up.Results: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P0.003). Women aged 50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P0.002).Conclusion:The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

Original languageEnglish
Pages (from-to)1384-1392
Number of pages9
JournalBritish Journal of Cancer
Volume104
Issue number9
DOIs
StatePublished - Apr 26 2011

Fingerprint

Breast Neoplasms
Mutation
Ovariectomy
Second Primary Neoplasms
Mastectomy

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., ... Narod, S. A. (2011). Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 104(9), 1384-1392. https://doi.org/10.1038/bjc.2011.120

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. / Metcalfe, K.; Gershman, S.; Lynch, Henry T.; Ghadirian, P.; Tung, N.; Kim-Sing, C.; Olopade, O. I.; Domchek, S.; McLennan, J.; Eisen, A.; Foulkes, W. D.; Rosen, B.; Sun, P.; Narod, S. A.

In: British Journal of Cancer, Vol. 104, No. 9, 26.04.2011, p. 1384-1392.

Research output: Contribution to journalArticle

Metcalfe, K, Gershman, S, Lynch, HT, Ghadirian, P, Tung, N, Kim-Sing, C, Olopade, OI, Domchek, S, McLennan, J, Eisen, A, Foulkes, WD, Rosen, B, Sun, P & Narod, SA 2011, 'Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers', British Journal of Cancer, vol. 104, no. 9, pp. 1384-1392. https://doi.org/10.1038/bjc.2011.120
Metcalfe, K. ; Gershman, S. ; Lynch, Henry T. ; Ghadirian, P. ; Tung, N. ; Kim-Sing, C. ; Olopade, O. I. ; Domchek, S. ; McLennan, J. ; Eisen, A. ; Foulkes, W. D. ; Rosen, B. ; Sun, P. ; Narod, S. A. / Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. In: British Journal of Cancer. 2011 ; Vol. 104, No. 9. pp. 1384-1392.
@article{7154f028a04b4de0baabdd71f56e6c57,
title = "Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers",
abstract = "Purpose:The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk.Patients and methods:Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up.Results: Overall, 149 subjects (18.4{\%}) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1{\%} for women with a BRCA1 mutation and was 28.5{\%} for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8{\%}; P0.003). Women aged 50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36{\%}; P0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95{\%} CI 0.30-0.76; P0.002).Conclusion:The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.",
author = "K. Metcalfe and S. Gershman and Lynch, {Henry T.} and P. Ghadirian and N. Tung and C. Kim-Sing and Olopade, {O. I.} and S. Domchek and J. McLennan and A. Eisen and Foulkes, {W. D.} and B. Rosen and P. Sun and Narod, {S. A.}",
year = "2011",
month = "4",
day = "26",
doi = "10.1038/bjc.2011.120",
language = "English",
volume = "104",
pages = "1384--1392",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

AU - Metcalfe, K.

AU - Gershman, S.

AU - Lynch, Henry T.

AU - Ghadirian, P.

AU - Tung, N.

AU - Kim-Sing, C.

AU - Olopade, O. I.

AU - Domchek, S.

AU - McLennan, J.

AU - Eisen, A.

AU - Foulkes, W. D.

AU - Rosen, B.

AU - Sun, P.

AU - Narod, S. A.

PY - 2011/4/26

Y1 - 2011/4/26

N2 - Purpose:The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk.Patients and methods:Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up.Results: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P0.003). Women aged 50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P0.002).Conclusion:The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

AB - Purpose:The objective of this study was to estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and cancer treatment-related factors modify the risk.Patients and methods:Patients were 810 women, with stage I or II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up.Results: Overall, 149 subjects (18.4%) developed a contralateral breast cancer. The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation. Women younger than 50 years of age at the time of breast cancer diagnosis were significantly more likely to develop a contralateral breast cancer at 15 years, compared with those older than 50 years (37.6 vs 16.8%; P0.003). Women aged 50 years with two or more first-degree relatives with early-onset breast cancer were at high risk of contralateral breast cancer, compared with women with fewer, or no first-degree relatives with breast cancer (50 vs 36%; P0.005). The risk of contralateral breast cancer was reduced with oophorectomy (RR 0.47; 95% CI 0.30-0.76; P0.002).Conclusion:The risk of contralateral breast cancer risk in BRCA mutation carriers declines with the age of diagnosis and increases with the number of first-degree relatives affected with breast cancer. Oophorectomy reduces the risk of contralateral breast cancer in young women with a BRCA mutation.

UR - http://www.scopus.com/inward/record.url?scp=79955474711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955474711&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.120

DO - 10.1038/bjc.2011.120

M3 - Article

VL - 104

SP - 1384

EP - 1392

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -